December 20, 2022
RegMed Investors’ (RMi) closing bell: thinking about getting back invested to the sector – DON’T and WAIT
December 19, 2022
RegMed Investors’ (RMi) closing bell: residual negativity haunts our universe of cell and gene therapy is severely damaged
December 16, 2022
RegMed Investors’ (RMi) closing bell: sector extends losses as selling pressure continues
December 15, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector bottoms
December 14, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector craters as Fed rate decision unfolds with more hikes next year
December 13, 2022
RegMed Investors’ (RMi) closing bell: indexes slow and some sector gains evaporate post CPI release
December 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector opened and closed higher as oversold were “recognized” in-front of CPI and Fed meeting report
December 9, 2022
RegMed Investors’ (RMi) closing bell: the bleed keeps spraying
December 8, 2022
RegMed Investors’ (RMi) closing bell: sector share pricing rise, not due to investors but, electronic trading and algorithms
December 6, 2022
RegMed Investors’ (RMi) closing bell: sentiment remains in the toilet, eroding daily and dependent on electronic trading crushing individual investors
December 5, 2022
RegMed Investors’ (RMi) closing bell: down shifting on a treacherous path
December 2, 2022
RegMed Investors’ (RMi) closing bell: The sector is what it is until it isn’t and even then, it doesn’t seem to be
December 2, 2022
RegMed Investors’ (RMi) closing bell: The sector is what it is, until it isn’t and even then, it doesn’t seem to be
December 1, 2022
RegMed Investors’ (RMi) closing bell: hitting the brakes as December begins
November 30, 2022
RegMed Investors’ (RMi) closing bell: month’s end with gift from Jerome, a slow 50-point basis-point rate hike in December
November 29, 2022
RegMed Investors’ (RMi) closing bell: the pendulum swung
November 28, 2022
RegMed Investors’ (RMi) closing bell: Being greedy when others are fearful is easier said than done
November 25, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector equities faltered Friday in a subdued trading session.
November 23, 2022
RegMed Investors’ (RMi) closing bell: gobble, gobble; share pricing heated-up
November 22, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy companies are swing to the upside after four (4) declining sessions
November 21, 2022
RegMed Investors’ (RMi) closing bell: short, holiday interrupted week
November 18, 2022
RegMed Investors’ (RMi) closing bell: this week the cell and gene therapy sector equities got “whacked’ on the knuckles, today it got a pat on the back!
November 17, 2022
RegMed Investors’ (RMi) closing bell: skipping stones and stocks
November 16, 2022
RegMed Investors’ (RMi) closing bell: tampering and dampening share price
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.